Research Analysts Offer Predictions for ALLO Q1 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Allogene Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.27) for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.14) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Several other brokerages also recently commented on ALLO. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a report on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.29.

Allogene Therapeutics Trading Down 0.6 %

Shares of Allogene Therapeutics stock opened at $1.62 on Friday. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.63. The stock has a market capitalization of $351.97 million, a price-to-earnings ratio of -1.04 and a beta of 1.02. The business’s 50 day simple moving average is $1.89 and its 200-day simple moving average is $2.28.

Insider Transactions at Allogene Therapeutics

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,866 shares of company stock worth $194,461. Insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new stake in shares of Allogene Therapeutics during the third quarter worth $116,000. The Manufacturers Life Insurance Company boosted its position in Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock valued at $1,361,000 after buying an additional 5,642 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Allogene Therapeutics by 541.5% during the third quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company’s stock valued at $130,000 after buying an additional 39,145 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Allogene Therapeutics in the third quarter worth about $91,000. Finally, EP Wealth Advisors LLC boosted its holdings in Allogene Therapeutics by 125.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock valued at $69,000 after acquiring an additional 13,625 shares during the period. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).